Studies

Thank you for your interest in volunteering for one of the University of Southern California Alzheimer’s Therapeutic Research Institute (USC ATRI) coordinated studies.

To participate, please find a trial that is right for you (or someone you love) and contact a clinical site near you. Each of our studies have different eligibility criteria.  While not everyone can join a trial, you can always become an advocate by sharing the trials with someone you know who might be able to participate.

To watch an informational video about why your participation in clinical trials is so important, click here.

We appreciate your support as we seek to prevent and treat Alzheimer’s disease.

Active Studies – Recruiting

Alzheimer’s Disease Neuroimaging Initiative logo
The Alzheimer’s Disease Neuroimaging Initiative (ADNI), a landmark study that began in 2004, is a public-private research partnership tasked with identifying biomarkers to detect Alzheimer’s disease (AD). The study has gathered and analyzed thousands of brain scans, genetic profiles and biomarkers in blood and cerebrospinal fluid (CSF) and was designed to enable researchers to follow AD as it progresses in an individual, from various points in the disease process.  ADNI3 will include 600 new participants age 55-90 and 600 rollover participants from ADNI2.

Learn more »

Alzheimer Prevention Trial Webstudy logo
If you are 50 years of age or older, now is the time to volunteer for the Alzheimer Prevention Trial Webstudy (APT Webstudy) and help us in the fight against Alzheimer’s disease. The APT Webstudy is an online cognitive assessment research study aimed at accelerating the enrollment time for clinical trials designed to prevent Alzheimer’s disease. The purpose of the webstudy is to develop a large online group of individuals who may be at higher risk for developing Alzheimer’s dementia, and who may be interested in participating in a prevention trial. By volunteering your time to take and share your memory and thinking test results, you will be helping to reduce the time it takes us to conduct our research.

Learn more »

DOD ADNI STUDY logo
The purpose of DOD ADNI is to examine the possible connections between Traumatic Brain Injury (TBI) and Posttraumatic Stress Disorder (PTSD), and the signs and symptoms of AD on Veterans as they age. Approximately 300 Vietnam War Veterans, ages 50-90 will be eligible to participate in this study

Learn more »

The LEADS study

The LEADS study – or the Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS) explores the development of early-onset Alzheimer’s disease and how it compares to the more common late-onset Alzheimer’s disease.  Better understanding of this form of the disease may ultimately lead to more effective treatments.  LEADS is a 2-year observational study designed to enroll 500 participants. Researchers are also recruiting cognitively normal volunteers for a 1-year comparison.

Learn more »

mind-study logo

The purpose of the Memory Improvement Through Nicotine Dosing (MIND) study is to determine whether daily transdermal nicotine (patch) will have a positive effect on early memory impairment in participants diagnosed with Mild Cognitive Impairment (MCI).  We are looking for healthy, non-smoking adults, age 55+.

Learn more »


Active Studies – Not Recruiting

The A4 Study logo
The landmark Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (A4 Study) enrolled 1,169 healthy older adults with normal memory but who might be at risk for Alzheimer’s due to family history of the disease and elevated levels of amyloid plaque in the brain. The primary study aims are to prevent the memory loss associated with the disease.

Learn more »

The Learn Study
The LEARN study was funded by the Alzheimer’s Association to support the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) study.  The LEARN study is a companion study to the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) study, a pioneering Alzheimer’s secondary prevention trial.

The ADNI Depression Project
The ADNI-Depression Project (ADNI-D) enrolled 120 participants who were experiencing symptoms of depression. The goal of the study is to determine whether imaging of the brain can help predict the onset and monitor the progression of cognitive change.
For more information, click here.
The SNIFF study
The purpose of the SNIFF study is to find out whether a type of insulin, when administered as a nasal spray, improves memory in adults with a mild memory impairment or Alzheimer’s disease (AD). The study enrolled 250 adults, age 55-85 who were diagnosed with amnestic mild cognitive impairment (aMCI) or early AD. There were 26 clinical sites involved. Scientists have learned that MCI has several subtypes. In the most common subtype with high probability of progression to Alzheimer’s disease, memory loss is the most prominent feature (other types of MCI feature other types of cognitive problems).

“We call the condition of memory impairment alone amnestic Mild Cognitive Impairment (aMCI),” says Dr. Ronald Petersen, director of the NIA-funded Mayo Alzheimer’s Disease Research Center.  “Researchers are particularly interested in the brain changes and memory loss of aMCI, because more people with this condition go on to develop AD than do people without it. We don’t yet know for sure whether aMCI is a separate condition or a transitional stage between normal aging and AD.”

Learn more »


Study Completed

The Connect study
The Connect study tested whether an oral, experimental drug, AZD0530 (saracatinib), would slow progression in early stage Alzheimer’s disease (AD). In its early stage after the medical diagnosis of Alzheimer’s disease, patients typically show some memory loss, but a majority of daily functions are intact, requiring some reminders or help organizing the day from others in the household. The University of Southern California, Alzheimer’s Therapeutic Research Institute served as the coordinating center, helping to enroll 159 participants at 23 clinical sites across the United States.

Learn more »


Not Recruiting

The Early Trial

The EARLY study
The EARLY Trial was looking to determine the Efficacy and safety of atabecestat in participants who are Asymptomatic at Risk for developing Alzheimer’s dementia. The study sponsor, Janssen, sought to use the latest advances to assess a participant’s risk associated with beta-amyloid and memory loss, and test whether a treatment that reduces amyloid formation would slow memory loss associated with Alzheimer’s disease (AD).

Elevations of liver enzymes, which were serious in nature, were observed in some study participants who received the Janssen BACE inhibitor, atabecestat. After a thorough evaluation of all available liver safety data from their studies, Janssen concluded that the benefit-risk ratio was no longer favorable to continue development of atabecestat for people who have late-onset preclinical stage Alzheimer’s disease.

Learn more »